NovoBind is an integrated animal health company utilizing next-generation biologics to target and neutralize key pathogens affecting producers and food safety. We target pathogens that cause >$1B of production losses and have been materially affected by the following:
A Regulatory ban on antibiotics, and;
Changing consumer sentiment.
We are continually expanding our portfolio and are currently focused on:
Food Safety, and;
SARS-CoV-2 Antibody Discovery Strategy
We are joining forces in the war on COVID-19 with a unique open source model. We’re donating our resources to develop custom nanobodies* for others to use in developing diagnostics and therapeutics that have a meaningful impact.
*Trademarked by Ablynx
Canadian coalition prepares to share research that could help against COVID-19
Canadian Coalition Fosters Global Collaboration in Fight Against COVID-19
NovoBind closes Series A, attracts key partners for the next stage of growth
Lallemand Animal Nutrition and NovoBind Announce Joint Development and Commercialization Agreement for Advanced Salmonella Biologics